Microbot Medical ( (MBOT) ) has provided an update.
On March 4, 2025, Microbot Medical Inc. announced the appointment of Paul Mullen as Vice President of Sales, marking the company’s first commercial hire as it prepares for the anticipated FDA clearance of its LIBERTY® Endovascular Robotic System in the second quarter of 2025. Mullen, with a strong background in endovascular sales and market development, will lead the company’s U.S. commercial sales efforts, focusing on building the sales strategy and infrastructure needed for a successful product launch.
More about Microbot Medical
Microbot Medical Inc. is a pre-commercial stage medical technology company focused on redefining endovascular robotics. The company is developing the world’s first single-use, fully disposable endovascular robotic system, aiming to improve the quality of care for patients and providers globally by making advanced robotic technologies more accessible in the endovascular space.
YTD Price Performance: 23.68%
Average Trading Volume: 4,169,650
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $48.99M
See more data about MBOT stock on TipRanks’ Stock Analysis page.
Trending Articles:
Questions or Comments about the article? Write to editor@tipranks.com